Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Name: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
License: Public Domain

National Cancer Institute (NCI)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

endometrial cancer, cancer of endometrium, carcinoma of endometrium, endometrial carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 283034
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.